MaxCyte, Inc. Stock London S.E.
Equities
MXCN
USU575801258
Advanced Medical Equipment & Technology
Financials (USD)
Sales 2024 * | 36.42M | Sales 2025 * | 46.63M | Capitalization | 474M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -45M | EV / Sales 2024 * | 8.9 x |
Net cash position 2024 * | 150M | Net cash position 2025 * | 120M | EV / Sales 2025 * | 7.59 x |
P/E ratio 2024 * |
-9.9
x | P/E ratio 2025 * |
-10.7
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.64% |
Latest transcript on MaxCyte, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
1st Jan change | Capi. | |
---|---|---|
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |